Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZZWNQ
ADC Name
huAb3v2.2-CZ
Synonyms
huAb3v2.2 CZ; huAb3v2.2CZ
   Click to Show/Hide
Organization
AbbVie, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
0.7
Structure
Antibody Name
huAb3v2.2
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
huAb3v2.2-CZ linker
Combination Type
AbbVie's CZ
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
26.7
nM
NCI-H847 cells
Lung small cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 26.70 nM Positive CD276 expression (CD276 +++/++)
Method Description
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model Lung small cell carcinoma NCI-H847 cells CVCL_1596
References
Ref 1 Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.